索磷布韦联合达拉他韦或司美匹韦治疗12周用于慢性丙型肝炎病毒基因1型非肝硬化受试者:一项随机临床试验
这项随机、开放标签、非劣效性试验纳入对聚乙二醇干扰素联合利巴韦林既往无应答或初治的HCV基因1型非肝硬化患者,比较索磷布韦联合达拉他韦或司美匹韦治疗12周的疗效与安全性。总体SVR12为96.8%,索磷布韦联合达拉他韦组为100%,索磷布韦联合司美匹韦组为93.3%,两组差异未达统计学显著,但因疗效差异具有临床相关性,未能确立司美匹韦组的非劣效性。
要点
- 索磷布韦联合达拉他韦组SVR12为100%(95%CI 94.5至100)。
- 索磷布韦联合司美匹韦组SVR12为93.3%(95%CI 83.8至98.2)。
- 两组SVR12绝对差异为6.6%(95%CI -15.0至0),未达统计学显著。
核心结论
- 总体SVR率为96.9%,索磷布韦联合达拉他韦组(100%)高于索磷布韦联合司美匹韦组(93.3%)。
- 尽管两组SVR12率无统计学显著差异,但因疗效差异具有临床相关性,未能确立索磷布韦联合司美匹韦对索磷布韦联合达拉他韦的非劣效性。
研究设计与样本
- 随机、开放标签、非劣效性试验,纳入对聚乙二醇干扰素联合利巴韦林既往无应答或初治的HCV基因1型非肝硬化患者。
- 患者随机接受索磷布韦(400 mg每日一次)联合达拉他韦(60 mg每日一次)或司美匹韦(150 mg每日一次)治疗12周。
- 分析纳入至少接受一剂研究药物的所有参与者;127例入组并随机化的患者中125例开始治疗(索磷布韦联合达拉他韦组n=65;索磷布韦联合司美匹韦组n=60)。
- 主要终点为治疗结束后12周持续病毒学应答(SVR12;HCV RNA采用COBAS TaqMan RT-PCR检测,检测和定量下限为12 UI/mL)。
- 研究注册于ClinicalTrials.gov(NCT02624063)。
主要发现
- 121例患者(96.8%)获得SVR12:索磷布韦联合达拉他韦组65例(100%)(95%CI 94.5至100),索磷布韦联合司美匹韦组56例(93.3%)(95%CI 83.8至98.2;绝对差异6.6%;95%CI -15.0至0)。
- 最常见不良事件为乏力(n=32,25.6%)、头痛(n=27,21.6%)和情绪波动(n=24,19.2%)。
- 无患者中断治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or simeprevir (SMV) in a randomized, open-label, noninferiority trial of patients infected with hepatitis C virus genotype 1, who were previously unresponsive to pegylated interferon and ribavirin or were treatment naive. METHODS: Patients were randomly assigned to receive SOF (400 mg once daily) plus DCV (60 mg once daily) or SMV (150 mg once daily) for 12 weeks. The analysis included all participants who received at least one dose of the study drugs. The primary endpoint was sustained virologic response 12 weeks after ending treatment (SVR12; hepatitis C virus RNA measured using COBAS TaqMan RT-PCR (lower limit of detection and quantification of 12 UI/mL)). This study was registered at ClinicalTrials.gov (NCT02624063). RESULTS: A total of 125 of 127 enrolled and randomized patients started treatment (n = 65 SOF + DCV; n = 60 SOF + SMV). SVR12 was attained in 121 patients (96.8%): 65 (100%) receiving SOF + DCV (95% confidence interval (CI), 94.5 to 100) and 56 (93.3%) receiving SOF + SMV (95% CI, 83.8 to 98.2; absolute difference, 6.6%; 95% CI, -15.0 to 0). The most common adverse events were fatigue (n = 32, 25.6%), headache (n = 27, 21.6%), and mood swings (n = 24, 19.2%). No patients discontinued therapy. CONCLUSIONS: The overall SVR rate was 96.9%; SOF + DCV (100%) was higher than that of SOF + SMV (93.3%). Despite no statistically significant intergroup difference in SVR12 rates, the noninferiority of SOF + SMV to SOF + DCV could not be established because the difference in efficacy was clinically relevant.
引用
- Pott-Junior H, Bricks G, Grandi G, et al. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. Clin Microbiol Infect. 2018. PMID: 29906601. doi:10.1016/j.cmi.2018.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。